Actions of vitamins D2 and D3 and 25-OHD3 in anticonvulsant osteomalacia.
In 54 epileptic outpatients treated for at least one year with anticonvulsants the bone mineral content (B.M.C.), an estimate of total body calcium, and serum calcium were measured before and during treatment with three doses of cholecalciferol (vitamin D3; 200, 100, and 50 mu-g daily) and 25-hydroxycholecalciferol (25-OHD3; 40, 20, and 10 mu-g daily) for 12 weeks. The results, when compared with the effects of calciferol (vitamin D2; 200, 100, and 50 mu-g daily) in 40 epileptic outpatients, showed different actions in anticonvulsant osteomalacia of vitamin D2 on the one hand and vitamin D3 and 25-OHD3 on the other. In the patients who received vitamin D2 an increase in B.M.C. was found whereas serum calcium was unchanged. The patients who received vitamin D3 or 25-OHD3 showed an increase in serum calcium but unchanged values of B.M.C. The results suggest that liver enzyme induction cannot alone explain anticonvulsant osteomalacia.
D000927:Anticonvulsants / Q000009:adverse effects*; D001842:Bone and Bones / Q000032:analysis; D002118:Calcium / Q000097:blood; D002762:Cholecalciferol / Q000627:therapeutic use*; D004790:Enzyme Induction / Q000187:drug effects; D004827:Epilepsy / Q000188:drug therapy; D004872:Ergocalciferols / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000201:enzymology; D008903:Minerals / Q000032:analysis; D010018:Osteomalacia / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy
D000927:Anticonvulsants; D004872:Ergocalciferols; D006887:Hydroxycholecalciferols; D008903:Minerals; D002762:Cholecalciferol; D002118:Calcium